The usefulness of the basophil activation test in monitoring specific immunotherapy with house dust mite allergens

Introduction In clinical practice, reliable tools for monitoring specific immunotherapy (SIT) are of utmost importance. Aim To assess the usefulness of the basophil activation test (BAT) in monitoring SIT in paediatric patients with allergy to house dust mites (HDM). Material and methods Thirty-one children qualified for SIT with HDM, of whom 21 completed the SIT during the observation period. The BAT was carried out prior to commencing the SIT (time point BAT1) and upon finishing the initial pack of allergy vaccine (cumulative dose of allergen 12487.5 PNU; BAT2), as well as after the second vaccine pack (cumulative dose of allergen 23750.0 PNU; BAT3). Peripheral blood of the patients was stimulated with allergen solutions in five concentrations from 0.00225 ng/ml to 22.5 ng/ml. Basophil activation was measured by CD63 expression in flow cytometry. Results For the allergen concentration of 0.225 ng/ml, a statistically significant decrease in median basophil activation was observed, from 51.29% at BAT1 to 8.48% at BAT2 (p = 0.004) and 4.21% at BAT3 (p < 0.001). For the allergen concentration of 0.0225 ng/ml, a statistically significant decrease was seen between BAT1 (1.72%) and BAT3 (0.21%, p = 0.01). Median CD-sens index decreased significantly from 1099.02 at BAT1 to 179.31 at BAT2 (p < 0.002) and 168.04 at BAT3 (p < 0.001). Conclusions There is a significant decrease in BAT results in the course of specific immunotherapy with HDM allergens in children, with the optimum allergen concentration for monitoring basophil response at 0.225 ng/ml. The CD-sens index seems to be a better monitoring parameter than the plain percentage of CD63-expressing basophils.

[1]  E. Czarnobilska,et al.  Comparison of the basophil activation test versus the nasal provocation test in establishing eligibility for specific immunotherapy. , 2016, Polskie Archiwum Medycyny Wewnetrznej.

[2]  P. Korošec,et al.  The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease , 2015, Allergy.

[3]  R. Dahl,et al.  Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. , 2014, The Journal of allergy and clinical immunology.

[4]  A. Ikinciogullari,et al.  Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response? , 2014, International Archives of Allergy and Immunology.

[5]  R. Cardona,et al.  Effect of immunotherapy on basophil activation induced by allergens in patients with atopic dermatitis. , 2014, Revista alergia Mexico.

[6]  S. Chirumbolo.  Immunotherapy in allergy and cellular tests , 2014, Human vaccines & immunotherapeutics.

[7]  E. McGowan,et al.  Update on the Performance and Application of Basophil Activation Tests , 2013, Current Allergy and Asthma Reports.

[8]  M. Calderón,et al.  Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. , 2012, Immunotherapy.

[9]  O. Gulbahar,et al.  Desensitization Effect of Preseasonal Seven-Injection Allergoid Immunotherapy with Olive Pollen on Basophil Activation: The Efficacy of Olive Pollen-Specific Preseasonal Allergoid Immunotherapy on Basophils , 2012, International Archives of Allergy and Immunology.

[10]  P. Korošec,et al.  Monitoring honeybee venom immunotherapy in children with the basophil activation test , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[11]  M. Borres,et al.  Basophil allergen threshold sensitivity, CD‐sens, IgE‐sensitization and DBPCFC in peanut‐sensitized children , 2012, Allergy.

[12]  S. Chirumbolo.  Basophil Activation Test in Allergy: Time for an Update? , 2012, International Archives of Allergy and Immunology.

[13]  W. Shreffler,et al.  Immunology in the Clinic Review Series; focus on allergies: basophils as biomarkers for assessing immune modulation , 2012, Clinical and experimental immunology.

[14]  F. Horak,et al.  Changes in basophil activation during grass‐pollen sublingual immunotherapy do not correlate with clinical efficacy , 2011, Allergy.

[15]  M. Skedinger,et al.  Basophil allergen threshold sensitivity, CD‐sens, is a measure of allergen sensitivity in asthma , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  P. Korošec,et al.  Immunoglobulin G‐dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  R. Dahl,et al.  Basophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapy , 2010, Clinical and molecular allergy : CMA.

[18]  L. Cardell,et al.  CD‐sens: a biological measure of immunological changes stimulated by ASIT , 2009, Allergy.

[19]  T. Bieber,et al.  Contribution of histamine metabolism to tachyphylaxis during the buildup phase of rush immunotherapy. , 2009, The Journal of allergy and clinical immunology.

[20]  A. Schuerwegh,et al.  Flow‐assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow‐up of wasp venom immunotherapy , 2007, Cytometry. Part B, Clinical cytometry.

[21]  L. Håkansson,et al.  Basophil Interleukin 4 and Interleukin 13 Production Is Suppressed during the Early Phase of Rush Immunotherapy , 2006, International Archives of Allergy and Immunology.

[22]  M. Palmqvist,et al.  Basophil allergen threshold sensitivity: a useful approach to anti‐IgE treatment efficacy evaluation , 2006, Allergy.

[23]  S. Durham,et al.  Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[24]  L. Söderström,et al.  Passive IgE‐sensitization by blood transfusion , 2005, Allergy.

[25]  B. Sachs,et al.  The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy , 2004, Allergy.

[26]  H. Vogelsang,et al.  Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy. , 2000, The Journal of allergy and clinical immunology.

[27]  L. Kanz,et al.  The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. , 1999, Blood.

[28]  D. MacGlashan.  Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. , 1993, The Journal of allergy and clinical immunology.

[29]  H. Jansen,et al.  Monitoring human basophil activation via CD63 monoclonal antibody 435. , 1991, The Journal of allergy and clinical immunology.

[30]  G. Porebski,et al.  [Basophil activation test--a practical approach to diagnosis of common respiratory allergy]. , 2015, Przeglad lekarski.

[31]  U. Demkow,et al.  The influence of sublingual immunotherapy on several parameters of immunological response in children suffering from atopic asthma and allergic rhinitis depending on asthma features. , 2014, Pneumonologia i alergologia polska.

[32]  G. Porebski,et al.  [The benefits of using basophil activation test as a diagnostic tool prior to specific immunotherapy with inhalant allergens]. , 2012, Przeglad lekarski.

[33]  P. Demoly,et al.  Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. II. Technical issues. , 2008, Journal of investigational allergology & clinical immunology.